Rani Therapeutics Holdings, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In July 2026, certain Purchasers exercised Pre-Funded Warrants to purchase 2,910,000 shares of Class A common stock, originally issued in the October 2025 Private Placement, on a cashless basis, in exchange for 2,909,657 shares of Class A common stock, par value $0.0001 per share. The Pre-Funded Warrants had an exercise price of $0.0001 per share, and no cash consideration was paid to the Company in connection with the exercises. The issuance of the shares of Class A common stock upon the cashless exercise of the Pre-Funded Warrants was exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 3(a)(9) thereof.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.